W. Land
About
In The Last Decade
W. Land
308 papers receiving 6.4k citations
Peers
Comparison fields: 5 of 145
- Transplantation 3.1k
- Surgery 2.9k
- Immunology 1.5k
- Public Health, Environmental and Occupational Health 859
- Molecular Biology 827
Countries citing papers authored by W. Land
This map shows the geographic impact of W. Land's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Land with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Land more than expected).
Fields of papers citing papers by W. Land
This network shows the impact of papers produced by W. Land. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Land. The network helps show where W. Land may publish in the future.
Co-authorship network of co-authors of W. Land
This figure shows the co-authorship network connecting the top 25 collaborators of W. Land. A scholar is included among the top collaborators of W. Land based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Land. W. Land is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 114 | |
| 3 | 456 | |
| 4 | Randomised trial comparing Tacrolimus and cyclosporin in the prevention of renal allograft rejection. European study | 3 |
| 5 | Microcirculation in organ transplantation | 6 |
| 6 | HLA matching and short/long-term outcome of cadaveric renal allografts: large single-centre data confirm the multicentre analyses. | 4 |
| 7 | Ten years' experience with cyclosporine monotherapy after renal transplantation. | 7 |
| 8 | Quality of life in diabetic patients prior to or after pancreas transplantation in relation to organ function. | 9 |
| 9 | 5 | |
| 10 | Organ replacement therapy : ethics, justice, commerce : first joint meeting of ESOT and EDTA/ERA, Munich, December 1990 | 3 |
| 11 | First clinical experiences with superoxide dismutase in kidney transplantation--results of a double-blind randomized study. | 28 |
| 12 | Incidence of fistulas following human pancreas transplantation--positive influence of reabsorption of pancreatic secretions by the peritoneum. | 4 |
| 13 | [Combined immunosuppression (cyclosporin, azathioprine, methylprednisolone) in patients at immunological risk after kidney transplantation]. | 1 |
| 14 | Cyclosporin bei Nierentransplantation | 1 |
| 15 | 4 | |
| 16 | [Further in-vitro studies on the mechanism of hyperacute xenogenic rejection reaction (HXAR)]. | 1 |
| 17 | 0 | |
| 18 | 2 | |
| 19 | 5 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.